Clinical Trial Update: Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias [Phase 1]

View source ↗

Summary

Phase 1 study of SGI-1776, a PIM kinase inhibitor, in relapsed or refractory leukemias was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• SGI-1776

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Relapsed/Refractory Leukemias | Phase 1 | Status: WITHDRAWN